Navigation Links
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Date:1/14/2009

Schering-Plough expects to respond to agency during first quarter

KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS(TM) (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy. The action letter includes proposed labeling for both indications and a request for supplemental data from the existing asenapine database. No additional clinical trials have been requested. The Company anticipates providing the requested information to the agency in the first quarter of 2009.

"We are pleased with the progress on the SAPHRIS filing and look forward to working with the agency to address its request, finalize the product labeling and gain approval," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "New treatments are needed in this therapeutic area and we believe that asenapine has the potential to be an important option in addressing this need."

Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the antipsychotic agent. The New Drug Application (NDA) for asenapine includes data from a clinical trial program involving more than 3,000 patients in schizophrenia and bipolar mania trials.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the plans for, the potential of and the potential market for asenapine. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed Oct. 29, 2008.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
2. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
3. MatTeks EpiDerm In Vitro Tissues Headed for Validation in Europe
4. Deer Farm Industry in Michigan Issues Statement on the Negative CWD Test Results at Kent County Deer Farm
5. U.S. FDA Issues Action Letter for Sugammadex
6. European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
7. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
8. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... or the "Company") (NASDAQ: ANTH ). Such investors ... by visiting the firm,s site: www.bgandg.com/anth .   ... and/or directors have violated Sections 10(b) and 20(a) of the ... ...
(Date:1/17/2017)... WASHINGTON , Jan. 17, 2017  In a ... CEO Jo Ann Jenkins outlines AARP,s priorities ... and Social Security, ensuring access to affordable health care ... In the letter Jenkins writes to President-elect Trump ... older Americans are counting on you to protect their ...
(Date:1/17/2017)... 2017 Immune Pharmaceuticals (NASDAQ: IMNP ... that it will hold a Satellite Symposium on February 20th, ... XVI in Munich, Germany . ... of Immunotherapy for the maintenance of remission in AML ... th , 2017 from 12:45 – 13:45 CET in ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has broken ... speed technology into the fabric of an entire community. A highlight of this ... wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership with ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... – will lecture to primary eye care practitioners on the latest breakthroughs in ... upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading ... a Principal in its IT Advisory Services practice . Rossi is the third ... market demand for strategic IT guidance grows, and the practice continues to expand.     , ...
(Date:1/17/2017)... ... 17, 2017 , ... Lynx Technology Partners (Lynx), ... security companies for consecutive years, today announced the appointment of four members to ... nomination process to a close and positions Lynx for even faster growth in ...
(Date:1/16/2017)... ... 17, 2017 , ... Recently, patients and staff from A Forever Recovery, a ... organizations in support of the annual Binder Park Zoo Halloween celebration known as the ... costumes of all designs coming out to enjoy games, face painting, and lots and ...
Breaking Medicine News(10 mins):